LL-37 and KPV are supplied strictly as laboratory research materials. They are not approved, intended or authorised for human consumption or any therapeutic use in this context. This article is written for qualified researchers and is not medical advice.
Two peptides, one problem: managing the immune response
Both compounds sit at the interface between innate immunity and inflammation, but they approach it from opposite ends of the size spectrum. LL-37 is the only cathelicidin-family antimicrobial peptide expressed in humans — a large, amphipathic molecule that both kills microbes directly and reshapes the immune response around it. KPV is the minimal C-terminal tripeptide of α-melanocyte-stimulating hormone, stripped down to three residues yet retaining a focused anti-inflammatory signal. One is a broad host-defence tool; the other is a precise off-switch for pro-inflammatory transcription. Put them side by side and the contrast is clean: antimicrobial-plus-immune versus targeted anti-inflammatory.
| LL-37 | KPV | |
|---|---|---|
| Class / peptide type | Cathelicidin antimicrobial peptide (CAMP) | Anti-inflammatory tripeptide (α-MSH fragment) |
| Structure / size | 37 amino acids · amphipathic α-helix · ~4493 Da | 3 amino acids (Lys-Pro-Val) · ~342 Da |
| Primary mechanism | Membrane disruption + immunomodulation (FPR2 / P2X7, LPS/LTA neutralisation) | Intracellular NF-κB inhibition (receptor-independent) |
| Cellular route | Inserts into microbial membranes; signals via immune-cell receptors | Uptake via PEPT1 / PEPT2 oligopeptide transporters |
| Main research focus | Antimicrobial / anti-biofilm, innate immunity, wound healing | IBD / gut mucosa and dermal inflammation |
| Typical pairing / stack | Studied largely on its own; vitamin D axis context | KLOW blend (TB-500 + BPC-157 + GHK-Cu + KPV) |
| Regulatory status | Research reagent — not MHRA/FDA approved | Research reagent — not MHRA/FDA approved |
LL-37: broad-spectrum host defence
LL-37 is a 37-amino-acid α-helical peptide cleaved from the C-terminus of the hCAP-18 precursor and expressed by neutrophils, epithelial cells and keratinocytes. It carries two mechanistic profiles at once. The first is direct antimicrobial action: its amphipathic helix and net positive charge (+6) drive selective insertion into negatively charged bacterial membranes, disrupting them through a "carpet" or toroidal-pore mechanism and producing broad activity against Gram-positive and Gram-negative bacteria, fungi and some enveloped viruses. Published in vitro work documents activity against clinically relevant pathogens including MRSA, Pseudomonas aeruginosa and E. coli, together with anti-biofilm activity of growing translational interest.
The second profile is immunomodulation. LL-37 binds formyl peptide receptor 2 (FPR2) and P2X7 on immune cells, neutralises bacterial LPS and lipoteichoic acid, and chemoattracts neutrophils, monocytes and T-cells while modulating dendritic-cell maturation. Its expression is strongly induced by active vitamin D, which grounds much of the research linking vitamin D status to innate immune competence. It has also been studied in wound-healing contexts for its role in keratinocyte migration and angiogenesis. Researchers sourcing the compound can buy LL-37 UK as a ≥99% purity reagent with a COA; the full mechanistic profile lives on the LL-37 knowledgebase page.
KPV: a focused anti-inflammatory signal
KPV is the C-terminal tripeptide (lysine-proline-valine, positions 11–13) of α-MSH. Despite its minimal size it retains the anti-inflammatory activity of the full-length hormone while shedding the melanocortin-receptor pigmentation and central effects — it is described as MC1R-sparing. Its mechanism is intracellular rather than receptor-mediated: KPV enters cells through the PEPT1 and PEPT2 oligopeptide transporters, reaches the nucleus and inhibits NF-κB signalling, the master switch for pro-inflammatory cytokine programmes. The downstream effect is suppression of TNF-α, IL-1β, IL-6 and chemokine production from activated immune cells.
Because PEPT1 is the principal oligopeptide transporter of the small intestine, KPV is one of the few peptides that retains bioactivity after oral administration — the basis for an active inflammatory bowel disease research programme in which rodent colitis models document reduced cytokine production and preserved mucosal architecture. A parallel line of dermal research examines topical KPV in contact- and atopic-dermatitis models, and the compound also appears in the four-part KLOW blend alongside TB-500, BPC-157 and GHK-Cu. Labs can buy KPV UK as research-grade material, with the receptor-independent mechanism detailed on the KPV knowledgebase page.
What the differences mean in a research context
The cleanest way to read the table is by scope. LL-37 is a wide instrument: it engages microbes and the immune system simultaneously, which makes it the natural choice for antimicrobial, anti-biofilm and innate-immunity research where the aim is to study host defence as a whole. KPV is a narrow one: it does essentially a single thing — dampen NF-κB-driven inflammation from inside the cell — which makes it well suited to models where the question is specifically about resolving inflammation without touching antimicrobial or pigmentation pathways.
Size drives much of the practical difference. LL-37's large amphipathic helix is what lets it perforate membranes, but it also means the peptide behaves like a structural molecule with membrane-level activity. KPV's three residues give it a very different profile: transporter-mediated uptake, oral bioavailability in preclinical models, and a receptor-independent action that avoids the systemic effects of full-length α-MSH. Where LL-37 tends to be studied on its own as a host-defence agent, KPV slots readily into combination research such as the KLOW blend, where it contributes the anti-inflammatory arm alongside distinct repair pathways.
There is some overlap worth noting — both peptides carry antimicrobial framing, and KPV's parent α-MSH is itself an immunomodulator — but the emphasis diverges sharply. LL-37 leads with killing and immune recruitment; KPV leads with cytokine suppression. Neither is a substitute for the other, and in a research setting they answer different questions.
The bottom line
LL-37 is the broad host-defence peptide — antimicrobial and immunomodulatory in one molecule — while KPV is the compact, targeted anti-inflammatory built around NF-κB suppression in the gut and skin. Choose by the question the model is asking: microbial and innate-immune work points to LL-37, focused inflammation work points to KPV. For research-grade material, see our dedicated pages to buy LL-37 UK and buy KPV UK, each ≥99% purity with a COA and free UK shipping.